SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001564590-21-058797
Filing Date
2021-11-30
Accepted
2021-11-30 16:18:06
Documents
13
Period of Report
2021-11-24
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K cccc-8k_20211124.htm   iXBRL 8-K 46232
2 EX-10.1 cccc-ex101_7.htm EX-10.1 281042
  Complete submission text file 0001564590-21-058797.txt   502999

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA cccc-20211124.xsd EX-101.SCH 5693
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE cccc-20211124_lab.xml EX-101.LAB 20082
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE cccc-20211124_pre.xml EX-101.PRE 11944
6 EXTRACTED XBRL INSTANCE DOCUMENT cccc-8k_20211124_htm.xml XML 3674
Mailing Address 490 ARSENAL WAY SUITE 200 WATERTOWN MA 02472
Business Address 490 ARSENAL WAY SUITE 200 WATERTOWN MA 02472 (617) 231-0700
C4 Therapeutics, Inc. (Filer) CIK: 0001662579 (see all company filings)

IRS No.: 475617627 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39567 | Film No.: 211459895
SIC: 2836 Biological Products, (No Diagnostic Substances)